insulin secretagogues  

Glimeripide - Linagliptin - Mitiglinide - Repaglinide      

Select
Display
Trial Studied trt Control trt patientstagsNCTROB Result

diabetes type 2

alogliptin
Seino, 2011alogliptinNCT01263509 -
Seino, 2011alogliptin -
Bosi , 2011alogliptinNCT00432276 -
Kaku, 2011alogliptin -
Rosenstock, 2010alogliptinNCT00395512 -
Rosenstock, 2009alogliptinNCT00286429 -
Pratley, 2009alogliptinNCT00286494 -
Pratley, 2009alogliptinNCT00286468 -
DeFronzo , 2008alogliptinNCT00286455 -
EXAMINE, 2011alogliptinplaceboNCT00968708negative
Nauck, 2009alogliptinplacebo (add on MET)NCT00286442Low risk of bias negative
gliclazide
Ristic, 2006gliclazidenateglinide (add on MET)Low risk of bias -
Matthews, 2005gliclazidepioglitazone (add on MET)Low risk of bias -
Khanolkar, 2008gliclaziderosiglitazone (add on MET) -
glimepiride
Charpentier, 2001glimepiride monotherapymetforminLow risk of bias -
glimeripide
Study 201 (Goldberg), 1996glimepirideplaceboLow risk of bias -
Schade, 1998glimepirideplaceboLow risk of bias -
Rosenstock, 1996glimepirideplaceboLow risk of bias -
Luis Bautista, 2003glimepirideplaceboLow risk of bias -
Kaneko, 1993glimepirideplacebo -
Study 202glimepirideplacebo -
Riddle, 1994glimepirideplacebo (add on insulin) -
LEAD-2 (Nauck) Sulf vs pbo, 2009glimepirideplacebo (add on MET)NCT00318461Low risk of bias -
Charpentier, 2001glimepirideplacebo (add on MET)Low risk of bias negative
Draeger, 1996glimepirideglibenclamideLow risk of bias -
Protocol 311glimepirideglibenclamide -
Charpentier (301F)glimepiridegliclazide -
Inukai, 2005glimepiridegliclazide or glibenclamide -
Sonnenberg, 1997glimepiride odglimepiride bid -
Clark (301), 1997glimepirideglipizide -
Dills, 1996glimepirideglyburideLow risk of bias -
glipizide
Goldsteinglipizidecontrol (add on MET) -
Rosenstock, 1993glipizideglyburide -
Birkeland, 1994glipizideglyburide -
Birkeland, 1994glipizideglyburideLow risk of bias -
Simonson, 1997glipizideplaceboLow risk of bias -
Testa, 1998glipizideplacebo -
Feinglos, 2005glipizide GITSplacebo (add on MET)Low risk of bias -
Nauck, 2007glipizidesitagliptin (add on MET) -
glyburide
Hermann, 1991glibenclamidec (add on MET) -
DeFronzo, 1995glyburidec (add on MET)Low risk of bias -
Erle, 1999glyburidec (add on MET) -
Marre (ass), 2002glibenclamidecontrol (add on MET)Low risk of bias -
Tosi, 2003glibenclamidecontrol (add on MET)Low risk of bias -
Blonde, 2002glyburidecontrol (add on MET)Low risk of bias -
Garber, 2003glyburidecontrol (add on MET) -
CV181-040saxagliptin + glyburideglyburide uptitrationNCT00313313 -
Garber, 2002glyburideplaceboLow risk of bias -
Vray, 1995glyburideplaceboLow risk of bias -
Garber, 2006glibenclamiderosiglitazone (add on MET)Low risk of bias -
linagliptin
Forst, 2010linagliptinNCT00309608Low risk of bias -
CAROLINA, 2012linagliptinglimepirideNCT01243424Low risk of bias suggesting
Gallwitz, 2012linagliptinglimepiride (add on MET)NCT00622284Low risk of bias -
linagliptin 1218.62 ongoing linagliptin low doselinagliptinNCT01012037Low risk of bias ongoing
OwenslinagliptinMetformin + sulfonylureaNCT00602472 -
Del PratolinagliptinplaceboNCT00621140Low risk of bias -
linagliptine 1218.50 ongoing linagliptinplaceboNCT00740051Low risk of bias ongoing
linagliptin1218.5 ongoing linagliptinplaceboNCT00328172 ongoing
linagliptin 1218.46 ongoing linagliptinplaceboNCT00798161 ongoing
Taskinenlinagliptinplacebo (add on MET)NCT00601250 -
linagliptin 1218.65 ongoing linagliptinplacebo (add on MET)NCT01215097Low risk of bias ongoing
linagliptin 1218.61 ongoing linagliptinplacebo (add on MET+TZD)NCT00996658 ongoing
Gomis, 2011linagliptinplacebo (add on pioglitazone)NCT00641043 -
Lewin, 2010linagliptinplacebo (add on SU)NCT00819091Low risk of bias -
linagliptin 1264.3 ongoing linagliptin + pioglitazonepioglitazoneNCT01183013 ongoing
mitiglinide
GaomitiglinidenateglinideNCT00461617Low risk of bias -
Kumashiro, 2007mitiglinideon top insulin glargine -
Kaku, 2009mitiglinideplacebo (on top pioglitazone) -
nateglinide
Marre, 2002nateglinideplaceboLow risk of bias -
Horton, 2000nateglinideplaceboLow risk of bias -
Hanefeld, 1990nateglinideplaceboLow risk of bias -
Saloranta, 2002nateglinideplaceboLow risk of bias -
Mari, 2005nateglinideplacebo -
Moses, 2001nateglinideplaceboLow risk of bias -
Goldberg, 1998repaglinideplaceboLow risk of bias -
Jovanovic, 2000repaglinideplaceboLow risk of bias -
Bech, 2003repaglinideplaceboLow risk of bias -
Li, 2009nategliniderepaglinide -
Li, 2007nategliniderepaglinide -
Ristic, 2006nateglinidegliclazide (add on MET)Low risk of bias -
repaglinide
Moses, 1999repaglinidecontrol (add on MET)Exploratory -
Landgraf, 1999repaglinideglibenclamideLow risk of bias -
Marbury, 1999repaglinideglibenclamide -
Wolffenbuttel, 1999repaglinideglibenclamideLow risk of bias -
Madsbad, 2001repaglinideglipizideLow risk of bias -
Lund, 2007repaglinidemetforminLow risk of bias -
Raskin, 2001repaglinideon top pioglitazone -
Raskin, 2001repaglinideon top rosiglitazone -
Raskin, 2000repaglinideon top troglitazone -
Chuang, 1999repaglinideplacebo -
Goldberg, 1998repaglinideplaceboExploratory -
Jovanovic, 2000repaglinideplaceboLow risk of bias -
Landin-Olsson, 1999repaglinideplacebo (on top bedtime NPH-insulin) -
saxagliptin
Kawamori, 2012saxagliptinNCT00654381 -
Forst, 2011Saxagliptin -
Fonseca, 2012saxagliptinNCT00960076 -
Nowicki, 2011saxagliptinNCT00614939 -
Yang, 2011saxagliptinNCT00661362 -
Nowicki, 2011saxagliptinNCT00614939 -
Göke, 2010saxagliptin -
Scheen , 2010saxagliptin -
Stenlöf , 2010Saxagliptin -
CV181-085saxagliptin plus metformin XR 1500mgmetformin up to 2000mgNCT00918138 -
SAVOR-TIMI 53, 2013saxagliptinplaceboNCT01107886negative
saxgliptin, renal studysaxagliptinplacebo (add on current treatment) -
CV181-057saxagliptinplacebo (add on insulin)NCT00757588 -
DeFronzo, 2009saxagliptinplacebo (add on MET)NCT00121667negative
Jadzinsky, 2009saxagliptinplacebo (add on MET)NCT00327015 -
CV181-066saxagliptinplacebo (add on MET)NCT00683657 -
CV181-080saxagliptinplacebo (add on MET)NCT00885378 -
Hollandersaxagliptinplacebo (add on TZD)NCT00295633 -
Rosenstock, 2008saxagliptinplacebo (monotherapy)NCT00950599 -
CV181-011saxagliptinplacebo (monotherapy)NCT00121641 -
CV181-038saxagliptinplacebo (monotherapy)NCT00316082 -
CV181-041saxagliptinplacebo (monotherapy)NCT00374907 -
saxagliptin vs sitagliptinsaxagliptinsitagliptin (add on MET) -
saxagliptinsaxagliptinglipizideLow risk of bias -
sitagliptin
Stafford , 2011sitagliptinNCT00451113 -
Reasner, 2011sitagliptincontrol (add on MET)NCT00482729) -
Arechavaleta, 2011sitagliptinglimepiride (add on MET)NCT00701090Low risk of bias -
Aschner, 2010sitagliptin monotherapymetforminNCT00449930Low risk of bias -
Derosa , 2010sitagliptin+piometformin+pio -
Goldstein, 2007sitagliptinplaceboNCT00103857negative
Hanefeld, 2007sitagliptinplacebonegative
Scott* (sit vs pbo), 2007sitagliptin 50mg bid monotherapyplacebonegative
Aschner, 2006sitagliptin monotherapyplaceboNCT00087516negative
Nonaka, 2008sitagliptin monotherapyplaceboNCT00371007Low risk of bias negative
Raz, 2006sitagliptin monotherapyplacebonegative
Barzilai, 2011sitagliptin monotherapyplaceboNCT00305604Low risk of bias -
Mohan , 2009sitagliptin monotherapyplaceboLow risk of bias -
Chan, 2008sitagliptin monotherapyplaceboLow risk of bias -
Vilsbøll, 2010sitagliptinplacebo (add on insulin+/-MET)NCT00395343Low risk of bias -
Charbonnel, 2006sitagliptinplacebo (add on MET)NCT0086515negative
Nauck, 2007sitagliptinplacebo (add on MET)NCT00094770negative
Scott** (sit vs pbo on top met), 2007sitagliptinplacebo (add on MET)negative
raz, 2008sitagliptinplacebo (add on MET)NCT00337610 -
Rosenstock , 2006sitagliptinplacebo (add on PIO)NCT00086502Low risk of bias -
Rosenstock (sit on top pio vs pbo), 2006sitagliptinplacebo (on top PIO)NCT00086502suggesting
Hermansen, 2007sitagliptinplacebo (on-top glimepiride+/- metformine)negative
Rigby , 2010sitagliptinrosiglitazone (add on MET) -
Al Sifri, 2011sitagliptinSulphonylurea (on top MET) -
Iwamoto , 2010sitagliptin monotherapyvogliboseLow risk of bias -
Scott* (sit vs glipi), 2007sitagliptin 50mg bid monotherapyglipizideLow risk of bias -
Goldstein (sit vs met), 2007sitagliptinmetformin -
Goldstein (sit+met vs met), 2007sitagliptinmetformin -
Pérez-Monteverde, 2011sitagliptinpioglitazoneNCT00541450Low risk of bias -
vildagliptin
NCT00101673vildagliptinNCT00101673 -
Pan, 2008vildagliptin monotherapyacarboseNCT00110240Low risk of bias -
Foley, 2009vildagliptin monotherapygliclazideNCT00102388Low risk of bias -
Filozof, 2009vildagliptingliclazide (add on MET)NCT00102466Low risk of bias -
Matthews , 2010vildagliptinglimepiride (add on MET)Low risk of bias -
CLAF237A 23104vildagliptin + METMETNCT00396357 -
Schweizer, 2009vildagliptinmetforminNCT00246619 -
Mimori, 2006vildagliptinplacebo -
Scherbaum [2], 2008vildagliptinplaceboNCT00101712Low risk of bias negative
Rosenstock, 2008vildagliptinplaceboNCT00237250Low risk of bias -
NCT00351832vildagliptinplaceboNCT00351832 -
Dejager [1], 2007vildagliptin monotherapyplaceboNCT00099905Low risk of bias negative
Pi-Sunyer, 2007vildagliptin monotherapyplaceboNCT00120536Low risk of bias suggesting
Pratley, 2006vildagliptin monotherapyplaceboLow risk of bias negative
Ristic, 2005vildagliptin monotherapyplacebonegative
Foley, 2011vildagliptin monotherapyplaceboNCT00260156 -
Kikuchi, 2009vildagliptin monotherapyplacebo -
Ahren, 2009vildagliptin monotherapyplaceboNCT00390520 -
Lukashevich , 2011vildagliptinplacebo (add on current therapy)NA -
Kikuchi, 2010vildagliptinplacebo (add on glimepiride)NCT00325117Low risk of bias -
Fonseca, 2007vildagliptinplacebo (add on insulin)NCT00099931Low risk of bias suggesting
Fonseca , 2008vildagliptinplacebo (add on insulin) -
Ahren, 2004vildagliptinplacebo (add on MET)Low risk of bias negative
Bosi, 2007vildagliptinplacebo (add on MET)NCT00099892Low risk of bias negative
Goodman, 2009vildagliptinplacebo (add on MET)Low risk of bias negative
Bosi, 2009vildagliptinplacebo (add on MET)NCT00382096 -
NCT00728351vildagliptinplacebo (add on MET)NCT00728351 -
NCT00822211vildagliptinplacebo (add on MET)NCT00822211 -
NCT00494884 (Wollmer)vildagliptinplacebo (add on MET)NCT00494884 -
NCT00396071vildagliptinplacebo (add on MET)NCT00396071 -
Garber, 2008vildagliptinplacebo (add on SU)NCT00099944Low risk of bias -
Garber, 2007vildagliptinplacebo (on top pioglitazone)NCT00099853negative
Rosenstock, 2009vildagliptinrosiglitazoneNCT00138619Low risk of bias -
Ferrannini, 2009vildagliptinSulfonylurea (add on to MET)NCT00106340Low risk of bias suggesting
GALIANT (Blonde), 2009vildagliptinTZD (add on MET)NCT00396227 -
NCT00368134vildagliptinvogliboseNCT00368134 -
Iwamoto, 2010vildagliptinvogliboseNALow risk of bias -
Schweizer, 2007vildagliptinmetforminNCT00099866negative
Goke, 2008vildagliptinmetformin -
Rosenstock** (vilda vs pio), 2007vildagliptin monotherapypioglitazoneNCT00101803Low risk of bias -
Bolli, 2008vildagliptinpioglitazone (add on MET)NCT00237237Low risk of bias negative
Rosenstock** (vilda + pio vs pio), 2007vildagliptinplacebo (add on TZD)NCT00101803Low risk of bias negative
Rosenstock* (vilda vs rosi), 2007vildagliptinrosiglitazoneNCT00099918Low risk of bias -